This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Patients Continuing On Sanofi's Lantus® Had Lower Blood Sugar Levels Than Those Who Switched To Insulin Detemir

BRIDGEWATER, N.J., June 14, 2014 /PRNewswire/ -- Sanofi US announced today results from a real world outcome study of type 2 diabetes (T2D) patients that show switching from Lantus® (insulin glargine [rDNA origin] injection) to insulin detemir demonstrated higher average blood sugar levels (A1C) and lower A1C reduction over a span of 12 months compared to maintaining patients on Lantus. Alternatively, switching patients from insulin detemir to Lantus resulted in a significantly lower A1C compared to maintaining patients on insulin detemir. The study findings were presented at the 74 th Scientific Sessions of the American Diabetes Association in San Francisco, Calif.

"The results of this real world study demonstrate variable patient outcomes when switching between basal insulin analogs," said Philip Levin, MD, Co-Director, Model Clinical Research, Greater Baltimore Medical Center, Baltimore, MD, and lead author of the study.  "It is important to understand that every patient is different and healthcare professionals need to determine the best treatment approach based on individual needs."   

This was a retrospective study (using an electronic medical records database) of two cohorts of adult T2D patients who had hemoglobin A1C (A1C) and weight measures at baseline that were examined between 2006 and 2012. Overall, 13,942 patients were included (female 54%, mean baseline age 58 year, average A1C 8.7%).  Cohort 1 was switched to insulin detemir (DET-S) from insulin glargine or continued on insulin glargine (GLA-C) and Cohort 2 was switched to insulin glargine (GLA-S) from insulin detemir or continued on insulin detemir (DET-S).

At one year follow up, in Cohort 1, compared with GLA-C patients, DET-S patients were significantly less persistent with treatment (52.5% vs 61.4%; P < 0.0001), had a significantly higher A1C (8.5% vs. 8.2%, P < 0.0001), experienced significantly less A1C reduction (-0.24% vs. -0.46%, P<0.0001) and a significantly lower proportion of patients achieved A1C <7% (21.0% vs. 26.1%, P<0.0001) and A1C <8% (45.7% vs. 53.2%, P<0.0001) despite a significantly higher proportion of DET-S patients using rapid acting insulin (57.7% vs. 52.5%, P<0.0001); there were no significant differences in hypoglycemia rate (DET-S: 2.1% vs. GLA-C: 2.1%, P=0.8894) or weight gain (DET-S: -0.35 lbs. vs. GLA-C: 0.21 lbs., P=0.3480) between the groups.  

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,132.70 -81.72 -0.45%
S&P 500 2,104.50 -6.24 -0.30%
NASDAQ 4,963.5270 -24.3630 -0.49%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs